Ibrutinib Receives Orphan Drug and Breakthrough Therapy Designation for cGVHD
The drug received breakthrough therapy and orphan drug designation as a monotherapy for the treatment of chronic graft-versus-host-disease.
On June 29, 2016 FDA granted Imbruvica (ibrutinib) Breakthrough Therapy designation and Orphan Drug designation as a monotherapy for the treatment of patients with chronic graft-versus-host-disease (cGVHD) after failure or one more lines of systematic therapy. This is the fourth Breakthrough Therapy designation for the drug, Reuters noted in a brief.
Imbruvica works by blocking Bruton’s tyrosine kinase (BTK). The BTK protein transmits signals that tell B cells to mature and multiply. Imbruvica targets and blocks BTK, inhibiting cancerous B cells to survive and spread. Imbruvica is currently being studied alone in combination with other treatments in several blood and solid tumor cancers and other serious illnesses.
Imbruvica is co-developed and commercialized by Pharmacyclics, an AbbVie company, and Janssen Biotech. AbbVie acquired Pharmacyclics and Imbruvica in March 2015 for $261.25 per share. AbbVie also acquired Stemcentrx in late April 2016. Both acquisitions are a strategic move for the company, which is looking to expand its oncology pipeline.
Source: AbbVie, Janssen Pharmaceuticals
Personalized CRISPR Therapy Successfully Treats Infant With Rare, Incurable CPS1 Deficiency
May 16th 2025A pediatric patient with a rare genetic disorder safely received a personalized CRISPR therapy, marking the first known case of a personalized CRISPR-based medicine administered to a single patient.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
